Skip to main content

Table 4 Analysis of lymphocyte subsets in the different groups at the acute phase (AP) and receding pandemic (CP) phases

From: Cross-sectional study of the relationship of peripheral blood cell profiles with severity of infection by adenovirus type 55

Lymphocyte subsets Healthy controls (n = 30) Phase Silent infection (n = 30) Minor infection (n = 27) Severe infection (n = 34) P-value
mDC/PBMC, % 0.53 ± 0.13 AP 1.09 ± 0.34b 0.81 ± 0.48b,c 0.53 ± 0.24c,d <0.0001a
CP 0.89 ± 0.43b,e ND 0.70 ± 0.30e 0.0014a
pDC/PBMC, % 0.24 ± 0.11 AP 0.42 ± 0.21b 0.39 ± 0.23b 0.22 ± 0.14c,d <0.0001a
CP 0.37 ± 0.22b ND 0.38 ± 0.12b,e 0.0048a
IFN-γ + CD4/CD3, % 23.09 ± 6.03 AP 17.41 ± 7.75b 16.13 ± 5.60b,d 23.94 ± 6.72c,d <0.0001a
CP 23.38 ± 6.81e ND 24.50 ± 8.73 0.0001a
IFN-γ + CD8/CD3, % 14.30 ± 5.65 AP 15.88 ± 8.17 12.53 ± 6.33 18.30 ± 8.23 0.0251
CP 23.30 ± 8.94b,e ND 18.40 ± 8.66d 0.0003a
IL-17 + CD4/CD3, % 2.06 ± 0.94 AP 1.74 ± 0.96 1.93 ± 0.89d 2.84 ± 1.19b,c,d 0.0004a
CP 3.37 ± 1.47b,e ND 3.04 ± 1.36b 0.0002a
IL-17 + CD8/CD3, % 0.22 ± 0.17 AP 0.54 ± 0.33b 0.40 ± 0.22b,d 0.25 ± 0.18c <0.0001a
   CP 0.81 ± 0.34b ND 0.74 ± 0.69b <0.0001a
  1. DC, dendritic cell; AP, acute phase; PBMC, peripheral blood mononuclear cell; CP, convalescent phase; ND, not determined.
  2. asignificant differences in the four groups by one-way ANOVA.
  3. bsignificant difference from the healthy control group.
  4. csignificant difference from the silent infection group.
  5. dsignificant difference from the minor infection group.
  6. esignificant difference from the AP within a group.